keyword
https://read.qxmd.com/read/38464895/subcutaneous-anakinra-in-the-management-of-refractory-mis-c-in-france
#21
JOURNAL ARTICLE
Perrine Dusser, Alexandre Belot, Fanny Bajolle, Charlotte Kevorkian-Verguet, Ulrich Meinzer, Frédéric Huet, Soizic Tiriau, Isabelle Kone-Paut
INTRODUCTION: Multisystemic inflammatory syndrome in children (MIS-C) is a therapeutic emergency and can lead to myocardial dysfunction (17%-75%) and heart failure (52%-53%). Intravenous immunoglobulins (IVIG) and corticosteroids (CST) have been validated for the management of this condition. Recent reports suggest that an interleukin-1 (IL-1) receptor antagonist, namely anakinra, may be a valuable add-on to the 2019 novel coronavirus disease (COVID-19) treatment for refractory patients...
2024: Frontiers in Pediatrics
https://read.qxmd.com/read/38458476/gut-immunomodulation-with-vedolizumab-prior-to-allogeneic-hematopoietic-stem-cell-transplantation-in-pediatric-patients-with-inflammatory-bowel-disease
#22
JOURNAL ARTICLE
Yogi Chopra, Karol Acevedo, Aleixo Muise, Karen Frost, Tal Schechter, Joerg Krueger, Muhammad Ali, Kuang-Yueh Chiang, V Y Kim, Eyal Grunebaum, Donna Wall
BACKGROUND: Inborn errors of immunity (IEI) are often associated with inflammatory bowel disease (IBD). IEI can be corrected by allogeneic hematopoietic stem cell transplantation (HSCT) however peri-transplantation intestinal inflammation may lead to increased risk of gut graft-versus-host disease (GVHD). Vedolizumab inhibits the homing of lymphocytes to the intestine and may attenuate gut GVHD, yet its role in preventing GvHD in pediatric patients with IEI-associated IBD has not been studied...
March 6, 2024: Transplantation and cellular therapy
https://read.qxmd.com/read/38454228/how-safe-are-biological-agents-in-pediatric-rheumatology
#23
JOURNAL ARTICLE
Emine Nur Sunar Yayla, Çişem Yıldız, Pelin Esmeray Şenol, Nihal Karaçayır, Deniz Gezgin Yıldırım, Sevcan A Bakkaloğlu
OBJECTIVE: Biologic therapy has changed the prognosis of patients with rheumatologic disease. Despite all benefits of the biological agents, adverse events may occur due to their long-term use. The aim of this study is to analyze the adverse events observed in pediatric patients who received biological treatment. MATERIALS AND METHODS: This retrospective observational cohort study was conducted between January 2010 and January 2022. File records of 139 patients used biological agents for rheumatologic diseases in a pediatric rheumatology clinic were evaluated...
March 2024: Turkish archives of pediatrics
https://read.qxmd.com/read/38454223/differentiating-multisystem-inflammatory-syndrome-in-children-from-kawasaki-disease-during-the-pandemic
#24
JOURNAL ARTICLE
Seher Şener, Ezgi Deniz Batu, Ümmüşen Kaya Akca, Erdal Atalay, Müşerref Kasap Cüceoğlu, Zeynep Balık, Özge Başaran, Tevfik Karagöz, Yasemin Özsürekçi, Yelda Bilginer, Seza Özen
OBJECTIVE: We aimed to delineate the distinctive characteristics that aid in distinguishing between Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) with KD-like manifestations during the pandemic. MATERIALS AND METHODS: We evaluated KD patients and MIS-C patients with KD-like symptoms admitted during the pandemic (between January 2021 and December 2022). RESULTS: Thirty-three MIS-C patients and 15 KD patients were included...
March 2024: Turkish archives of pediatrics
https://read.qxmd.com/read/38444608/p2x7-receptor-inhibition-alleviates-mania-like-behavior-independently-of-interleukin-1%C3%AE
#25
JOURNAL ARTICLE
Flóra Gölöncsér, Mária Baranyi, Pál Tod, Fruzsina Maácz, Beáta Sperlágh
Purinergic dysfunctions are associated with mania and depression pathogenesis. P2X7 receptor (P2X7R) mediates the IL-1β maturation via NLRP3 inflammasome activation. We tested in a mouse model of the subchronic amphetamine (AMPH)-induced hyperactivity whether P2X7R inhibition alleviated mania-like behavior through IL-1β. Treatment with JNJ-47965567, a P2X7R antagonist, abolished AMPH-induced hyperlocomotion in wild-type and IL-1α/β-knockout male mice. The NLRP3 inhibitor MCC950 failed to reduce AMPH-induced locomotion in WT mice, whereas the IL-1 receptor antagonist anakinra slightly increased it...
March 15, 2024: IScience
https://read.qxmd.com/read/38441807/adult-onset-still-s-disease-aosd-advances-in-understanding-pathophysiology-genetics-and-emerging-treatment-options
#26
REVIEW
Sara Bindoli, Chiara Baggio, Andrea Doria, Paolo Sfriso
Adult-onset Still's disease (AOSD) is a multisystemic complex disorder clinically characterised by episodes of spiking fever, evanescent rash, polyarthritis or diffuse arthralgias; multiorgan involvement may develop according to the hyper-inflammatory extent. The pathogenesis of AOSD is not completely recognised. The central role of macrophage activation, which results in T helper 1 (Th1) cell cytokine activation, is well established. Pro-inflammatory cytokines such as interleukin (IL)-1, IL-6 and IL-18 play a fundamental role in disease onset and progression...
March 5, 2024: Drugs
https://read.qxmd.com/read/38441301/macrophage-activation-syndrome-in-patients-with-systemic-juvenile-idiopathic-arthritis-on-anti-interleukin-1-or-6-therapy
#27
JOURNAL ARTICLE
Kadir Ulu, Emil Aliyev, Elif Kılıç Könte, Ayşe Tanatar, Şeyma Türkmen, Şeyda Doğantan, Zehra Kızıldağ, Belde Kasap Demir, Deniz Gezgin Yıldırım, Gülçin Otar Yener, Kübra Öztürk, Özge Baba, Ceyhun Açarı, Gülşah Kılbaş, Sema Nur Taşkın, Fatih Haşlak, Şengül Çağlayan, Esra Bağlan, Hatice Adıgüzel Dundar, Özge Başaran, Kenan Barut, Şerife Gül Karadağ, Taner Coşkuner, Hafize Emine Sönmez, Selçuk Yüksel, Mukaddes Kalyoncu, Sevcan A Bakkaloğlu, Erbil Ünsal, Ayşenur Paç Kısaarslan, Yelda Bilginer, Nuray Aktay Ayaz, Özgür Kasapçopur, Seza Özen, Betül Sözeri
OBJECTIVES: The aim of this study is to investigate the effect of anti-interleukin (IL)-1/-6 biologics on systemic juvenile idiopathic arthritis (sJIA)-associated macrophage activation syndrome (MAS). METHODS: Demographic, clinical, and laboratory data of patients followed up with a diagnosis of sJIA-associated MAS assessed from sixteen pediatric rheumatology centers across the country. The clinical and laboratory features of MAS developing while on biological drugs were compared with those without this treatment...
March 5, 2024: Rheumatology
https://read.qxmd.com/read/38434533/high-pretreatment-disease-burden-as-a-risk-factor-for-infectious-complications-following-cd19-chimeric-antigen-receptor-t-cell-therapy-for-large-b-cell-lymphoma
#28
JOURNAL ARTICLE
Maeve A O'Reilly, Lorna Neill, Simon M Collin, Neil Stone, Deborah Springell, Jeremy Mensah, Kathleen P L Cheok, Katarzyna Jalowiec, Reuben Benjamin, Andrea Kuhnl, Claire Roddie, Robin Sanderson
Infection has emerged as the chief cause of non-relapse mortality (NRM) post CD19-targeting chimeric antigen receptor T-cell therapy (CAR-T) therapy. Even though up to 50% of patients may remain infection-free, many suffer multiple severe, life-threatening, or fatal infectious events. The primary aim of this study was to explore severe and life-threatening infections post licensed CAR-T therapy in large B-cell lymphoma, with a focus on the role of disease burden and disease sites in assessing individual risk...
January 2024: HemaSphere
https://read.qxmd.com/read/38430119/second-line-immunotherapy-in-new-onset-refractory-status-epilepticus
#29
REVIEW
Aurélie Hanin, Eyal Muscal, Lawrence J Hirsch
Several pieces of evidence suggest immune dysregulation could trigger the onset and modulate sequelae of new onset refractory status epilepticus (NORSE), including its subtype with prior fever known as febrile infection-related epilepsy syndrome (FIRES). Consensus-driven recommendations have been established to guide the initiation of first- and second-line immunotherapies in these patients. Here, we review the literature to date on second-line immunotherapy for NORSE/FIRES, presenting results from 28 case reports and series describing the use of anakinra, tocilizumab, or intrathecal dexamethasone in 75 patients with NORSE...
March 2, 2024: Epilepsia
https://read.qxmd.com/read/38424321/novel-presentation-of-major-histocompatibility-complex-class-ii-deficiency-with-hemophagocytic-lymphohistiocytosis
#30
JOURNAL ARTICLE
Fayhan J Alroqi, Musaab A Alhezam, Abdullah I Almojali, Tlili Barhoumi, Nouf Althubaiti, Yousef Alharbi, Mohammed A Al Balwi, Abdulrahman Alrasheed
PURPOSE: Major histocompatibility complex (MHC) class II deficiency is one of the combined immune deficiency disorders caused by defects in the MHC class II regulatory genes leading to abnormal T cells development and function. Therefore, patients mainly present with increased susceptibility to infections, diarrhea, and failure to thrive. In this report, we present one MHC class II deficient patient with a novel presentation with Hemophagocytic Lymphohistiocytosis (HLH). METHODS: Immunophenotyping of lymphocyte subpopulations and HLA-DR expression was assess by flow cytometry...
March 1, 2024: Journal of Clinical Immunology
https://read.qxmd.com/read/38415679/adverse-events-of-biological-agents-in-pediatric-rheumatologic-diseases
#31
JOURNAL ARTICLE
Merve Cansu Polat, Saniye Mertek, Zeynep Birsin Özçakar, Elif Çelikel, Fatma Aydın, Zahide Ekici Tekin, Atilla Halil Elhan, Banu Çelikel Acar, Nilgün Çakar
OBJECTIVES: To evaluate adverse events (AEs) in pediatric patients with rheumatologic diseases being treated with approved or off-label biologic agents (BAs). METHODS: This observational, retrospective, multicenter study was conducted from 2010 to 2022 in patients under 18 years of age with rheumatic diseases who were receiving interleukin-1 antibodies (Anti-IL1), interleukin-6 antibodies (Anti-IL6), and tumor necrosis factor alpha inhibitors (anti-TNF). Efficacy, AEs, and timing of AEs were collected from electronic medical records...
February 28, 2024: Postgraduate Medicine
https://read.qxmd.com/read/38407734/exploring-il-1-inhibition-in-chronic-refractory-idiopathic-myocarditis-emerging-insights-and-perspectives
#32
JOURNAL ARTICLE
Maddalena Alessandra Wu, Emanuele Bizzi, Antonio Brucato
No abstract text is available yet for this article.
February 26, 2024: Internal and Emergency Medicine
https://read.qxmd.com/read/38398405/inflammatory-complications-in-chronic-granulomatous-disease
#33
REVIEW
Alexandros Grammatikos, Andrew R Gennery
Chronic granulomatous disease (CGD) is a rare inborn error of immunity that typically manifests with infectious complications. As the name suggest though, inflammatory complications are also common, often affecting the gastrointestinal, respiratory, urinary tracts and other tissues. These can be seen in all various types of CGD, from X-linked and autosomal recessive to X-linked carriers. The pathogenetic mechanisms underlying these complications are not well understood, but are likely multi-factorial and reflect the body's attempt to control infections...
February 15, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38398338/analysis-of-anakinra-therapy-for-the-deficiency-of-interleukin-1-receptor-antagonist-through-clinical-evidence
#34
REVIEW
Kathryn Pillai, Joshua Pillai, Jun Ling
BACKGROUND: Deficiency of interleukin-1 receptor antagonist (DIRA) is a rare life-threatening autosomal recessive autoinflammatory disease with symptoms including but not limited to osteomyelitis, periostitis, and systemic inflammation. DIRA is developed from the loss-of-function biallelic mutations of the IL1RN gene that encodes IL-1 receptor antagonist (IL-1RA), leading to the unchecked pro-inflammatory signaling and subsequent systemic inflammation. Thus, anakinra as the recombinant IL-1RA has become the primary drug to treat DIRA...
February 10, 2024: Journal of Clinical Medicine
https://read.qxmd.com/read/38397412/therapeutic-potential-of-il-1-antagonism-in-hidradenitis-suppurativa
#35
REVIEW
Laura Calabrese, Dalma Malvaso, Giulia Coscarella, Flaminia Antonelli, Alessandra D'Amore, Niccolò Gori, Pietro Rubegni, Ketty Peris, Andrea Chiricozzi
The immunopathogenesis of HS is partially understood and exhibits features of an autoinflammatory disease; it is associated with the potential involvement of B cells and the contribution of Th1 or Th17 cell subsets. Recently, the pathogenic role of both innate immunity and IL-1 family cytokines in HS has been deeply investigated. Several agents targeting the IL-1 family pathway at different levels are currently available and under investigation for the treatment of HS. HS is still characterized by unmet clinical needs and represents an expanding field in the current scientific research...
February 1, 2024: Biomolecules
https://read.qxmd.com/read/38391885/biomaterials-functionalized-with-inflammasome-inhibitors-premises-and-perspectives
#36
REVIEW
Norina Vinţeler, Claudia Nicoleta Feurdean, Regina Petkes, Reka Barabas, Bianca Adina Boşca, Alexandrina Muntean, Dana Feștilă, Aranka Ilea
This review aimed at searching literature for data regarding the inflammasomes' involvement in the pathogenesis of oral diseases (mainly periodontitis) and general pathologies, including approaches to control inflammasome-related pathogenic mechanisms. The inflammasomes are part of the innate immune response that activates inflammatory caspases by canonical and noncanonical pathways, to control the activity of Gasdermin D. Once an inflammasome is activated, pro-inflammatory cytokines, such as interleukins, are released...
January 28, 2024: Journal of Functional Biomaterials
https://read.qxmd.com/read/38378749/a-pivotal-role-for-the-il-1%C3%AE-and-the-inflammasome-in-preterm-labor
#37
JOURNAL ARTICLE
T E Lopez, H Zhang, E Bouysse, F Neiers, X Y Ye, C Garrido, M Wendremaire, Frédéric Lirussi
During labor, monocytes infiltrate massively the myometrium and differentiate into macrophages secreting high levels of reactive oxygen species and of pro-inflammatory cytokines (i.e. IL-1β), leading to myometrial contraction. Although IL-1β is clearly implicated in labor, its function and that of the inflammasome complex that cleaves the cytokine in its active form, has never been studied on steps preceding contraction. In this work, we used our model of lipopolysaccharide-induced preterm labor to highlight their role...
February 20, 2024: Scientific Reports
https://read.qxmd.com/read/38377098/relationship-between-biologic-modifying-agents-and-development-of-latent-tuberculosis-in-pediatrics
#38
JOURNAL ARTICLE
Tugba Bedir Demirdag, Aslinur Ozkaya Parlakay, Fatma Aydin, Gokcen Dilsa Tugcu, Beytullah Santaflıoglu, Saliha Kanik Yuksek, Belgin Gulhan, Guzin Cinel, Banu Celikel Acar
INTRODUCTION: Biologic modifying agents are associated with an increased risk for infection with mycobacteria. The aim of this study is to document patients who received different biologic modifying therapies in our pediatric rheumatology department and the possibility of development of tuberculosis (TB). METHODOLOGY: This retrospective study was conducted in Ankara City Hospital. Pediatric patients who were treated with biologic modifying agents between 2010-2020 were documented...
January 31, 2024: Journal of Infection in Developing Countries
https://read.qxmd.com/read/38376736/practical-approach-to-diagnosis-and-management-of-il-1-mediated-autoinflammatory-diseases-caps-traps-mkd-and-dira
#39
JOURNAL ARTICLE
Kader Cetin Gedik, Zehra Serap Arici, Ovgu Kul Cinar, Facundo Garcia-Bournissen, Micol Romano, Erkan Demirkaya
Systemic autoinflammatory diseases (SAIDs) are a group of rare genetic and nongenetic immune dysregulatory disorders associated with high morbidity and mortality if left untreated. Therefore, early diagnosis and initiation of targeted treatment is vital in SAID patients to control the disease activity and prevent long-term immune-mediated damage. A specific group of genetically defined SAIDs is associated with increased inflammasome-mediated production of active interleukin (IL)-1. Even though progress in immunobiology and genetics has brought forth diagnostic tools and novel treatments that have been described in the literature extensively, many challenges remain in the clinical setting...
February 20, 2024: Paediatric Drugs
https://read.qxmd.com/read/38376724/initial-diagnosis-of-extranodal-nk-t-cell-lymphoma-in-pericardial-fluid-with-concomitant-hemophagocytic-lymphohistiocytosis-hlh
#40
JOURNAL ARTICLE
Amani Khasawneh, Georgeann McGuinness, Nicholas Ward
Extranasal natural killer/T-cell lymphoma arising in the heart is rare and typically presents with non-specific clinical symptoms, necessitating a biopsy for a definitive diagnosis. We report an unusual case of a 48-year-old male who initially presented with chest pain and shortness of breath. Subsequent diagnosis via pericardial fluid analysis, including flow cytometry and immunohistochemical stains, revealed extranasal NK/T-cell lymphoma without sinonasal involvement. The analysis identified neoplastic lymphoid cells expressing CD2, cytoplasmic CD3, Epstein-Barr virus, and CD56 and exhibiting increased Ki-67 staining...
March 2024: Journal of Hematopathology
keyword
keyword
48370
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.